AGN-195263
195263-010
Phase 3 small_molecule terminated
Quick answer
AGN-195263 for Dry Eye Syndromes is a Phase 3 program (small_molecule) at Allergan Pharmaceuticals International Limited with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Allergan Pharmaceuticals International Limited
- Indication
- Dry Eye Syndromes
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- terminated